Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes

The logopenic variant of primary progressive aphasia (lvPPA) has been associated with Alzheimer disease, although this relationship is still subject to debate. The purpose of this study is to determine the frequency of amyloid biomarkers in patients with lvPPA, and record any potential clinical or t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology 2015-06, Vol.262 (6), p.1463-1472
Main Authors: Matías-Guiu, Jordi A., Cabrera-Martín, María Nieves, Moreno-Ramos, Teresa, Valles-Salgado, María, Fernandez-Matarrubia, Marta, Carreras, José Luis, Matías-Guiu, Jorge
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Alzheimer's disease
Amyloid - metabolism
Aphasia
Aphasia, Primary Progressive - classification
Aphasia, Primary Progressive - complications
Aphasia, Primary Progressive - diagnostic imaging
Aphasia, Primary Progressive - metabolism
Autopsies
Biomarkers
Brain Mapping
Cognition Disorders - etiology
Dementia
Female
Fluorodeoxyglucose F18
Hospitals
Humans
Longitudinal Studies
Male
Medical research
Medicine
Medicine & Public Health
Metabolism
Middle Aged
Neurology
Neuropsychological Tests
Neuroradiology
Neurosciences
Original Communication
Positron-Emission Tomography
Semantics
Statistics, Nonparametric
Tomography
Tomography, X-Ray Computed
Topography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The logopenic variant of primary progressive aphasia (lvPPA) has been associated with Alzheimer disease, although this relationship is still subject to debate. The purpose of this study is to determine the frequency of amyloid biomarkers in patients with lvPPA, and record any potential clinical or topographic differences between patients with and without amyloid deposits. We conducted cognitive examination and positron-emission tomography studies with fluorodeoxyglucose ( 18 F) and florbetapir ( 18 F) in a cohort of 16 patients diagnosed with lvPPA. We evaluated the prevalence of amyloid deposits as well as any clinical and metabolic differences between the groups with and without significant presence of amyloid deposits. Eleven patients (69 %) were considered amyloid-positive. The amyloid-positive group displayed less metabolic activity in the left temporoparietal region than the control group, while the amyloid-negative group showed lower metabolism in the left temporoparietal region extending to the anterior temporal and basal frontal regions. The percentage of change in patients with clinical and FDG-PET follow-up did not differ between the amyloid-positive and amyloid-negative subgroups. The frequency of amyloid-positive cases confirms that lvPPA is frequently associated with Alzheimer disease. Amyloid-negative patients show a different cerebral metabolic pattern. These findings show the relevance of using amyloid PET to study lvPPA, and also suggest that the logopenic variant may not be specific to Alzheimer disease in certain cases.
ISSN:0340-5354
1432-1459
DOI:10.1007/s00415-015-7738-z